Business context and reporting period
Labcorp Holdings’ Form 10-K reports the fiscal year ended December 31, 2020, with comparisons to 2019. The company operates two segments: Diagnostics (Dx) and Drug Development (DD). Results were heavily shaped by the COVID-19 pandemic: COVID testing offset pandemic-related weakness in the underlying business.
Financial performance and liquidity
Amounts are in millions of dollars except per-share data, percentages and ratios.
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $13,978.5 | $11,554.8 | +21.0% |
| Gross profit | $4,952.8 | $3,252.5 | +52.3% |
| Operating income | $2,445.4 | $1,330.2 | +83.8% |
| Net earnings attributable to Labcorp | $1,556.1 | $823.8 | +88.9% |
| Diluted EPS | $15.88 | $8.35 | +90.2% |
| Operating cash flow | $2,135.3 | $1,444.7 | +47.8% |
| Capital expenditures | $381.7 | $400.2 | −4.6% |
Gross margin rose to 35.4% from 28.2%; operating margin rose to 17.5% from 11.5%. Operating cash flow less capital expenditures was $1,753.6, versus $1,044.5 in 2019. Cash and cash equivalents increased to $1,320.8 from $337.5. Current assets were $5,125.4 and current liabilities $3,078.5 at year-end.
Year-end debt, including current and long-term debt and net of issuance costs, was $5,795.7. The company had $5,450.0 aggregate principal of Senior Notes and a $375.0 term loan balance; $376.7 of debt was classified as current. Its $1.0 billion revolving facility had no borrowings outstanding, with $997.0 available after letters of credit. The company reported compliance with debt covenants. It repaid $412.2 of Senior Notes during 2020.
Material changes versus 2019
- Revenue growth reflected 19.0% organic growth, 1.8% from acquisitions and 0.4% favorable foreign currency translation, partly offset by a 0.2% disposition impact. COVID-19 testing contributed 24.1 percentage points to organic growth, while the organic Base Business declined 5.1%.
- Dx revenue increased 32.2% to $9,253.4 and operating income rose to $2,634.9 from $1,086.0; its operating margin expanded to 28.5% from 15.5%. Dx COVID-19 testing drove much of the increase. In the fourth quarter, Dx Base Business volumes remained below prior year by high single digits.
- DD revenue grew 6.5% to $4,877.7, but operating income fell 90.9% to $37.3, with margin down to 0.8% from 9.0%. The principal driver was $450.5 of DD goodwill and other asset impairments, alongside pandemic-related delays and higher personnel costs.
- Consolidated goodwill and other asset impairment charges totaled $462.1, including $422.4 of goodwill impairment. The company also recorded restructuring charges of $40.6 and reported a 29.8% effective tax rate, up from 25.3%, partly reflecting impairment charges that were not deductible or generated tax assets requiring valuation allowances.
Outlook, commentary and risks
Management did not provide a numerical 2021 revenue or earnings outlook in the supplied filing text. It expected COVID-19 to continue affecting the business through 2021 and potentially beyond, while vaccine rollout could gradually reduce COVID testing demand below 2020 levels. Management expected other diagnostic testing and COVID-19 and non-COVID-19 drug development activity to grow in 2021. Planned 2021 capital expenditures were approximately 4.0% of revenue.
Key uncertainties include the pandemic’s duration and severity, recovery in routine testing and clinical trials, test reimbursement and utilization controls, supply and staffing constraints, and collections. PAMA reduced revenue from affected payers by approximately $72.0 in 2020; 2021 reductions were suspended under the CARES Act, but the filing discusses further rate-setting changes from 2023. The company also highlighted competition, customer and payer consolidation, regulatory and compliance exposure, cybersecurity, foreign exchange, and leverage risks.
Unusual matters include $36.5 of COVID-related costs in cost of revenues and $10.4 in SG&A; a $17.0 COVID-related receivables reserve recorded as a revenue reduction; and $25.4 of investment impairments attributed to COVID-19. Labcorp returned $132.1 of CARES Act provider relief funds in the fourth quarter after determining the intended negative financial impact no longer applied; the return had no reported 2020 financial-statement impact. The company disclosed pending litigation and regulatory inquiries related to the 2019 AMCA vendor data breach and other legal matters, but stated it could not estimate reasonably probable losses for certain proceedings. It reported an unmodified audit opinion and effective internal control over financial reporting.
Important facts for investors to verify
- How much of 2020’s earnings and cash-flow growth is sustainable as COVID testing demand normalizes, and how quickly Dx Base Business volumes recover.
- Whether DD operating performance rebounds after the impairment charges and pandemic-related trial delays.
- Actual 2021 capital spending and the effect of future PAMA reimbursement rates, payer policies and test utilization controls.
- Debt repayment and refinancing plans, including the $375.0 term loan classified as current and due in 2021, and compliance with leverage covenants.
- Developments and potential costs in AMCA-related litigation and regulatory inquiries, other contingencies, and the collectability of receivables amid elevated patient responsibility.